Amneal Pharmaceuticals, Inc.
AMRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AMRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AMRX
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of essential medicines, operating through three segments: Affordable Medicines, Specialty, and AvKARE.
Key risk: High debt and negative equity
BioSniper Score
Based on 6 of 6 signals
Market Cap
$6.11B
Cash Runway
96.3 moLead Asset
imatinib (Approved)Next Catalyst
Phase3_Topline · Dec 31, 2026Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 14 clinical trials · 3 catalysts · 2 FDA decisions for Amneal Pharmaceuticals, Inc..
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of essential medicines, operating through three segments: Affordable Medicines, Specialty, and AvKARE.
- Amneal operates three reportable segments: Affordable Medicines (over 280 product families), Specialty (branded CNS and endocrine drugs), and AvKARE (pharmaceutical distribution) [sec_mda · as of 2026-02-27].
- As of 2026-06-30, the company reported total revenue of $796.2M, net income of $57.7M, cash & equivalents of $139.6M, shareholders' equity of -$112.1M, and total debt of $2,576.3M [sec].
- The company has a pipeline of over 110 programs and more than 290 marketed commercial products, with a strategy to move toward complex, difficult-to-manufacture products [sec · filed 2026-03-25].
- In 2025, Amneal received approval for its first two inhalation products and two new biosimilars, and launched the Brekiya autoinjector for migraine and cluster headache [sec · filed 2026-03-25].
- Amneal has a strategic collaboration with Metsera for developing, manufacturing, and commercializing GLP-1 therapies [sec · filed 2025-03-25].
What works
- Amneal has large-scale, in-house manufacturing facilities globally, including one of the largest U.S. manufacturing footprints in the industry, providing operational control and scale [sec · filed 2026-03-25].
- The company is shifting its portfolio toward complex, high-barrier-to-entry products (e.g., inhalation, biosimilars, injectables), which can offset pricing erosion in its base generics business [sec · filed 2026-03-25].
- Specialty segment growth is driven by key branded products such as CREXONT, RYTARY, UNITHROID, and the Brekiya autoinjector, providing revenue diversification [sec · filed 2026-03-25].
- The AvKARE distribution segment has delivered strong double-digit growth, contributing to overall revenue expansion [sec · filed 2025-03-25].
What to weigh
- Amneal has negative shareholders' equity of -$112.1M and a high total debt of $2,576.3M as of 2026-06-30, indicating significant leverage [sec].
- The company faces systemic cost pressures in the healthcare environment and relies on a strategy to navigate unpredictable pricing and reimbursement changes [sec · filed 2026-03-25].
- Amneal's business is subject to risks from consolidation of major customers, dependence on third-party suppliers for raw materials, and regulatory changes in FDA approval processes [sec · filed 2018-05-16].
- The company's ability to meet working capital and debt obligations depends on economic conditions, trade policy (including tariffs), and product demand, which are outside its control [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Amneal has a large pipeline and broad product portfolio.
“Creating a carefully funded research and development platform to feed a large and diverse pipeline of over 110 pipeline programs to supplement our current portfolio of more than 290 marketed commercial products”
SEC filings · March 25, 2026
Amneal's strategy focuses on complex products.
“Executing on a strategy to steadily move up the value chain to more complex and difficult-to-manufacture products that offset the steady erosion of our base Affordable Medicines business”
SEC filings · March 25, 2026
Amneal has a GLP-1 collaboration with Metsera.
“Established our strategic collaboration with Metsera for developing, manufacturing and commercializing GLP-1s”
SEC filings · March 25, 2025
Catalyst timeline
- 2026-12-31 · Phase3_Topline — Phase 3 Topline: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib — Topline results from a Phase 3 study evaluating osimertinib plus bevacizumab in a cancer indication; outcome may impact Amneal's oncology pipeline perception.
- 2027-02-03 · Phase3_Topline · erlotinib — Phase 3 Topline: Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth F — Topline results from a Phase 3 study of erlotinib as adjuvant therapy; data will inform the drug's potential in early-stage NSCLC.
- 2028-07-01 · Phase3_Topline · carboplatin — Phase 3 Topline: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxe — Topline results from a Phase 3 study combining chemotherapy with immunotherapy; outcome could influence combination treatment standards.
Risks & what to watch (4)›
Key risks
- High debt and negative equity — Total debt of $2,576.3M and negative shareholders' equity of -$112.1M as of 2026-06-30, indicating significant financial leverage [sec].
- Customer concentration and consolidation — The company faces risks from the continuing trend of consolidation of certain customer groups, which could reduce bargaining power [sec · filed 2018-05-16].
- Dependence on third-party suppliers — Amneal relies on third-party suppliers and distributors for raw materials, creating supply chain vulnerability [sec · filed 2018-05-16].
- Regulatory and healthcare reform risks — Changes in FDA approval requirements, healthcare reform, and reimbursement policies could impact product approvals and sales [sec · filed 2018-05-16].
What to watch
- Phase 3 topline results for osimertinib + bevacizumab combination study expected by 2026-12-31 [catalyst].
- Phase 3 topline results for erlotinib versus observation in resected EGFR-mutant NSCLC expected by 2027-02-03 [catalyst].
- Phase 3 topline results for carboplatin/paclitaxel/pembrolizumab regimen expected by 2028-07-01 [catalyst].
- Earnings reports and updates on GLP-1 collaboration with Metsera [sec · filed 2025-03-25].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Amneal Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Amneal Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
96.3 months
D/E 113.35 · 3% dilution
Lead: Approved
4 candidates
3 upcoming, next in ~123d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 5.5%
- Days to cover
- 7.3
- Shares short
- 11,507,430
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AMRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Amneal Pharmaceuticals, Inc.?
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of essential medicines, operating through three segments: Affordable Medicines, Specialty, and AvKARE.
What is Amneal Pharmaceuticals, Inc.'s lead drug candidate?
Amneal Pharmaceuticals, Inc.'s most advanced tracked candidate is imatinib (Approved).
What is Amneal Pharmaceuticals, Inc.'s next catalyst?
Amneal Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (" — expected December 31, 2026.
Who is the CEO of Amneal Pharmaceuticals, Inc.?
Mr. Chirag K. Patel is the chief executive officer of Amneal Pharmaceuticals, Inc. (AMRX).
Where is Amneal Pharmaceuticals, Inc. headquartered?
Amneal Pharmaceuticals, Inc. (AMRX) is headquartered in Bridgewater, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.